These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 25022850)

  • 21. Adjuvant rituximab therapy in pemphigus: a single-center experience of 18 cases.
    Baum S; Gilboa S; Greenberger S; Pavlotsky F; Trau H; Barzilai A
    J Dermatolog Treat; 2013 Dec; 24(6):427-30. PubMed ID: 23521340
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A single cycle of rituximab for the treatment of severe pemphigus.
    Joly P; Mouquet H; Roujeau JC; D'Incan M; Gilbert D; Jacquot S; Gougeon ML; Bedane C; Muller R; Dreno B; Doutre MS; Delaporte E; Pauwels C; Franck N; Caux F; Picard C; Tancrede-Bohin E; Bernard P; Tron F; Hertl M; Musette P
    N Engl J Med; 2007 Aug; 357(6):545-52. PubMed ID: 17687130
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combined treatment with immunoadsorption and rituximab leads to fast and prolonged clinical remission in difficult-to-treat pemphigus vulgaris.
    Behzad M; Möbs C; Kneisel A; Möller M; Hoyer J; Hertl M; Eming R
    Br J Dermatol; 2012 Apr; 166(4):844-52. PubMed ID: 22092243
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of rituximab in pemphigus: experience of the German Registry of Autoimmune Diseases.
    Kasperkiewicz M; Eming R; Behzad M; Hunzelmann N; Meurer M; Schulze-Koops H; von Wussow P; Hertl M; Zillikens D; Freivogel K; Dörner T; Schmidt E
    J Dtsch Dermatol Ges; 2012 Oct; 10(10):727-32. PubMed ID: 22577946
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment of severe pemphigus with rituximab: report of 12 cases and a review of the literature.
    Cianchini G; Corona R; Frezzolini A; Ruffelli M; Didona B; Puddu P
    Arch Dermatol; 2007 Aug; 143(8):1033-8. PubMed ID: 17709662
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Two courses of rituximab (anti-CD20 monoclonal antibody) for recalcitrant pemphigus vulgaris.
    Faurschou A; Gniadecki R
    Int J Dermatol; 2008 Mar; 47(3):292-4. PubMed ID: 18289336
    [TBL] [Abstract][Full Text] [Related]  

  • 27. First-line treatment of pemphigus vulgaris with a combination of rituximab and high-potency topical corticosteroids.
    Ingen-Housz-Oro S; Valeyrie-Allanore L; Cosnes A; Ortonne N; Hüe S; Paul M; Wolkenstein P; Chosidow O
    JAMA Dermatol; 2015 Feb; 151(2):200-3. PubMed ID: 25354242
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rituximab in childhood and juvenile autoimmune bullous diseases as first-line and second-line treatment: a case series of 13 patients.
    Kianfar N; Dasdar S; Mahmoudi H; Tavakolpour S; Balighi K; Daneshpazhooh M
    J Dermatolog Treat; 2022 Mar; 33(2):869-874. PubMed ID: 32589481
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Analysis of current therapy and clinical outcome in childhood pemphigus vulgaris.
    Mabrouk D; Ahmed AR
    Pediatr Dermatol; 2011; 28(5):485-93. PubMed ID: 21883426
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A comprehensive analysis of treatment outcomes in patients with pemphigus vulgaris treated with rituximab.
    Ahmed AR; Shetty S
    Autoimmun Rev; 2015 Apr; 14(4):323-31. PubMed ID: 25499920
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin.
    Ahmed AR; Spigelman Z; Cavacini LA; Posner MR
    N Engl J Med; 2006 Oct; 355(17):1772-9. PubMed ID: 17065638
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of rituximab therapy in patients with pemphigus vulgaris: first report from Turkey.
    Uzun S; Bilgiç Temel A; Akman Karakaş A; Ergün E; Özkesici B; Eskiocak AH; Erat A; Uğurlu N; Nazlım B; Koç S; Bozkurt S; Dicle Ö; Alpsoy E; Yılmaz E
    Int J Dermatol; 2016 Dec; 55(12):1362-1368. PubMed ID: 27653507
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term follow-up after rituximab for steroid-dependent idiopathic nephrotic syndrome.
    Kemper MJ; Gellermann J; Habbig S; Krmar RT; Dittrich K; Jungraithmayr T; Pape L; Patzer L; Billing H; Weber L; Pohl M; Rosenthal K; Rosahl A; Mueller-Wiefel DE; Dötsch J
    Nephrol Dial Transplant; 2012 May; 27(5):1910-5. PubMed ID: 22076431
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Low-dose rituximab as an adjuvant therapy in pemphigus.
    Gupta J; Raval RC; Shah AN; Solanki RB; Patel DD; Shah KB; Badheka AD; Shah KB; Aggarwal NK; Ravishankar V
    Indian J Dermatol Venereol Leprol; 2017; 83(3):317-325. PubMed ID: 28366912
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of severe pemphigus with a combination of immunoadsorption, rituximab, pulsed dexamethasone and azathioprine/mycophenolate mofetil: a pilot study of 23 patients.
    Kasperkiewicz M; Shimanovich I; Meier M; Schumacher N; Westermann L; Kramer J; Zillikens D; Schmidt E
    Br J Dermatol; 2012 Jan; 166(1):154-60. PubMed ID: 21910700
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adjuvant rituximab treatment for pemphigus: A retrospective study of 45 patients at a single center with long-term follow up.
    Kim TH; Choi Y; Lee SE; Lim JM; Kim SC
    J Dermatol; 2017 Jun; 44(6):615-620. PubMed ID: 28186358
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anti-CD20 monoclonal antibody (rituximab) in the treatment of pemphigus.
    Arin MJ; Engert A; Krieg T; Hunzelmann N
    Br J Dermatol; 2005 Sep; 153(3):620-5. PubMed ID: 16120153
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A prospective study comparing patients with early and late relapsing pemphigus treated with rituximab.
    Saleh MA
    J Am Acad Dermatol; 2018 Jul; 79(1):97-103. PubMed ID: 29408700
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Assessment of the rate of long-term complete remission off therapy in patients with pemphigus treated with different regimens including medium- and high-dose corticosteroids.
    Almugairen N; Hospital V; Bedane C; Duvert-Lehembre S; Picard D; Tronquoy AF; Houivet E; D'incan M; Joly P
    J Am Acad Dermatol; 2013 Oct; 69(4):583-8. PubMed ID: 23850258
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rituximab for the treatment of corticosteroid-refractory pemphigus vulgaris with oral and skin manifestations.
    Craythorne E; du Viver A; Mufti GJ; Warnakulasuriya S
    J Oral Pathol Med; 2011 Sep; 40(8):616-20. PubMed ID: 21385212
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.